• In August 2026, Bristol Myers Squibb received accelerated FDA approval for ZENBEXUS (iberdomide) in combination with daratumumab, hyaluronidase-fihj and dexamethasone to treat adults with relapsed or refractory multiple myeloma after at least one prior therapy, making it the first FDA-approved CELMoD in this setting.
• The approval is the first in relapsed or refractory multiple myeloma based on achieving minimal residual disease-negative complete responses, highlighting how highly sensitive MRD testing is starting to influence regulatory decisions and drug development in oncology.
• We’ll now examine how this first-in-class CELMoD approval, anchored on MRD-negative complete responses, could reshape Bristol Myers Squibb’s investment narrative.

AI is about to change healthcare. These 44 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Bristol-Myers Squibb Investment Narrative Recap

Bristol Myers Squibb’s investment case rests on whether its newer oncology and cardiovascular drugs, plus business development, can offset looming patent expiries on Eliquis and Opdivo. The accelerated ZENBEXUS approval adds a new mechanism in multiple myeloma and may modestly strengthen the near term pipeline catalyst set, but the biggest overhang remains execution on late stage assets and how quickly the legacy portfolio erodes.

Among recent announcements, the reported merger talks with AstraZeneca are the most relevant in context of ZENBEXUS. A potential combination would overlay an already complex story around patent cliffs and pipeline durability with additional regulatory and integration risk, at the same time as BMS is introducing first in class agents that could be central to its standalone growth narrative.

Yet against this potential upside, investors should be aware that litigation and regulatory scrutiny could still...

Bristol-Myers Squibb’s narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This implies a 6.2% yearly revenue decline but an earnings increase of about $1.3 billion from $7.3 billion today.

Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, in line with its current price.

Exploring Other Perspectives

Some analysts were far more optimistic, assuming BMS could lift earnings to about US$10.2 billion by 2029, but the ZENBEXUS decision may ultimately shift both those upbeat assumptions and the more cautious views around patent, pricing and pipeline risk.

Explore 6 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth 23% less than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 4 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.

Seeking Other Investments?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 50 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.